Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL

NCT01217749 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Prolymphocyctic Leukemia
Richter's Transformation

Interventions

DRUG: PCI-32765
DRUG: ofatumumab

Sponsor

Pharmacyclics LLC.

Collaborators

[object Object]